SCHEMBL3974885

SCHEMBL3974885

CCO[PH](=O)OCC.CCO[PH](=O)OCC

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.30
ALDH1A1 P00352 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL35436 1.00
Methane SCHEMBL14562663 0.96
SCHEMBL346640 0.96
Propane SCHEMBL3976635 0.96
Methane SCHEMBL7159879 0.96
SCHEMBL3359535 0.96
SCHEMBL7204269 0.96
Ethane SCHEMBL1199897 0.96
SCHEMBL20539620 0.96
SCHEMBL31252440 0.96

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114716476-A Carbazole derivative-based self-assembled monolayer hole transport material and synthetic method and application thereof 嘉兴学院 2022-07-08 CN claimed
CN-114349794-A Diphosphonic acid platinum complex and synthesis method and application thereof 南京医科大学 2022-04-15 CN claimed
US-12296304-B2 Membrane for water filtration AQUAPORIN A/S (DK) 2025-05-13 US disclosed
EP-4277731-B1 PROCESS FOR PREPARING A MEMBRANE AQUAPORIN AS (DK) 2024-10-09 EP disclosed
US-20240058768-A1 MEMBRANE FOR WATER FILTRATION AQUAPORIN A/S (DK) 2024-02-22 US disclosed
EP-4277731-A1 MEMBRANE FOR WATER FILTRATION Aquaporin A/S (DK) 2023-11-22 EP disclosed
CN-116745025-A membrane for water filtration 水通道蛋白有限公司 2023-09-12 CN disclosed
WO-2022152748-A1 MEMBRANE FOR WATER FILTRATION AQUAPORIN A/S (DK) 2022-07-21 WO disclosed
EP-3573992-B1 SUBSTITUTED BICYCLIC PYRIMIDINE-BASED COMPOUNDS AND COMPOSITIONS AND USES THEREOF TSANTRIZOS YOULA S (CA) 2022-04-13 EP disclosed
US-11279719-B2 Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof Tsantrizos, Youla S. (CA) 2022-03-22 US disclosed
CN-108767299-A A kind of fuel cell compound organic phospho acid high temperature proton exchange film and preparation method thereof 中国科学院上海有机化学研究所 2018-11-06 CN disclosed
US-6114175-A AMYLOID-BINDING COMPOUNDS WHICH ARE NON-AZO DERIVATIVES OF CHRYSAMINE G TO DETERMINE DEGREE OF BRAIN DEPOSITS QUANTITATIVELY CHARACTERIZED BY AMYLOIDOSIS; DOWN'S SYNDROME; PREVENT CELL DEGENERATION; RADIOACTIVE IMAGING UNIVERSITY OF PITTSBURGH (US) 2000-09-05 US disclosed
EP-0977815-A1 ALKYL, ALKENYL AND ALKYNYL CHRYSAMINE G DERIVATIVES FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND $i(IN VIVO) IMAGING AND PREVENTION OF AMYLOID DEPOSITION UNIVERSITY OF PITTSBURGH (US) 2000-02-09 EP disclosed
WO-1998047969-A1 ALKYL, ALKENYL AND ALKYNYL CHRYSAMINE G DERIVATIVES FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION UNIVERSITY OF PITTSBURGH (US) 1998-10-29 WO disclosed
EP-0646119-B1 QUATERNARY NITROGEN-CONTAINING PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM AS WELL AS DENTAL CALCULUS AND PLAQUE PROCTER & GAMBLE PHARMA (US) 1998-07-15 EP disclosed
EP-0849272-A1 Quaternary nitrogen-containing phosphonate compounds for treating abnormal calcium and phosphate metabolism as well as dental calculus and plaque Procter & Gamble Pharmaceuticals, Inc. (US) 1998-06-24 EP disclosed
US-5770586-A Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism amd methods of treating and preventing dental calculus and plaque THE PROCTER & GAMBLE COMPANY (US) 1998-06-23 US disclosed
EP-0646119-A1 QUATERNARY NITROGEN-CONTAINING PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM AS WELL AS DENTAL CALCULUS AND PLAQUE PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 1995-04-05 EP disclosed
US-5391743-A Treating osteoporosis, rheumatoid arthritis, osteoarthritis PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 1995-02-21 US disclosed
WO-1993024498-A1 QUATERNARY NITROGEN-CONTAINING PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM AS WELL AS DENTAL CALCULUS AND PLAQUE PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 1993-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11279719-B2 Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof GGPS1, TYMP, FDPS KMT2A 4729/4885ALDH1A1 3329/4885TSHR 4777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.